Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17053358 | 1.00 | HSD17B10 (0.36) | HSD17B10ALDH1A1SMN1; SMN2KMT2ASLC6A9 | |
| SCHEMBL560792 | 0.95 | HSD17B10 (0.39) | HSD17B10ALDH1A1SMN1; SMN2KMT2ASLC6A9 | |
| SCHEMBL15518427 | 0.95 | HSD17B10 (0.39) | HSD17B10ALDH1A1SMN1; SMN2KMT2ASLC6A9 | |
| SCHEMBL437100 | 0.88 | LMNA (0.36) | HSD17B10ALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL12238070 | 0.88 | LMNA (0.36) | HSD17B10ALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL1241402 | 0.87 | GAA (0.41) | ALDH1A1SMN1; SMN2KMT2AMEN1CHRM2 | |
| SCHEMBL14522328 | 0.87 | CHRM5 (0.35) | HSD17B10SLC6A9TSHRCHRM5CHRM3 | |
| SCHEMBL12038457 | 0.87 | CHRM5 (0.35) | HSD17B10SLC6A9TSHRCHRM5CHRM3 | |
| SCHEMBL25039379 | 0.85 | HSD17B10 (0.33) | HSD17B10SLC6A9 | |
| SCHEMBL23662688 | 0.85 | SLC6A9 (0.33) | HSD17B10SLC6A9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389697-B1 | SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES | ANTAROS MEDICAL AB (SE) | 2020-12-16 | — | — | EP | disclosed |
| US-9718929-B2 | Chelating amphiphilic polymers | KONINKLIJKE PHILIPS N.V. (NL) | 2017-08-01 | — | — | US | disclosed |
| US-20150247008-A1 | CHELATING AMPHIPHILIC POLYMERS | KONINKL PHILIPS NV (NL) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150247008-A1 | CHELATING AMPHIPHILIC POLYMERS | SLC30A5, SLC30A6, ABCB4 | HSD17B10 4296/4885ALDH1A1 4768/4885SMN1; SMN2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.